Ellicott City, M.D., April 22, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced new developments to its landmark Site Advocacy Group initiative. TheSite Advocacy Group (SAG) initiative enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools, and technologies. Since its inception in early 2014, the SAG initiative has exercised considerable impact on the clinical research landscape by inciting important dialogue between site professionals and industry leaders related to current and evolving practices.
“The level of engagement seen from site and industry representatives with SCRS’ SAG initiative has exceeded even our most optimistic expectations,” states Christine Pierre, SCRS President. “Sites are able to provide direct feedback and see their knowledge and perspective embraced by industry leaders. The sites’ voice truly is being heard, and SCRS is pleased to announce additional opportunities for involvement in 2015.”
SCRS Circle of Sustainability Sponsor INC Research will launch two SAGs in 2015: Investigator Payment and Scientific and Operational. SCRS Site Engagement Partner Acurian will be launching the European Centralized Enrollment and Retention SAG.
SCRS is currently partnered with TransCelerate BioPharma Inc. on the Site Qualification and Training, Risk Based Monitoring, Investigator Registry, Shared Investigator Platform, and Common Protocol Template SAGs. SCRS is also in collaboration with Global Impact Partner Lilly for the Innovation SAG.
The opportunity to participate in a SAG is available to all SCRS members. To inquire about joining a SAG, please contact Allyson Small, Director of Operations, SCRS.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.